Bayesian Capital Management, LP Tg Therapeutics, Inc. Transaction History

Bayesian Capital Management, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$13.32 - $19.19 $816,516 - $1.18 Million	61,300 Added 138.48%	105,567 $1.88 Million
Q1 2024 May 15, 2024	SELL	$13.02 - $21.3 $934,836 - $1.53 Million	-71,800 Reduced 61.86%	44,267 $673,000
Q4 2023 Feb 14, 2024	BUY	$6.68 - $18.81 $775,327 - $2.18 Million	116,067 New	116,067 $1.98 Million
Q2 2023 Aug 14, 2023	BUY	$15.48 - $35.0 $706,925 - $1.6 Million	45,667 New	45,667 $1.13 Million
Q4 2022 Feb 14, 2023	SELL	$5.01 - $11.83 $25,125 - $59,327	-5,015 Reduced 18.15%	22,610 $267,000
Q3 2022 Nov 14, 2022	BUY	$4.57 - $8.4 $27,077 - $49,770	5,925 Added 27.3%	27,625 $164,000
Q2 2022 Aug 15, 2022	BUY	$3.74 - $10.66 $81,158 - $231,322	21,700 New	21,700 $92,000

345

87.6M

2.35M

1.7M

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.86B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

Get notified when there are updates to the investment portfolio of Bayesian Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Bayesian Capital Management, LP with notifications on news.